CERo Therapeutics Holdings, Inc.
CERO
$5.40
-$0.10-1.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.99% | -23.75% | 66.71% | 918.60% | 52.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.50% | 12.19% | 86.90% | 186.68% | 113.29% |
| Operating Income | -5.50% | -12.19% | -86.90% | -186.68% | -113.29% |
| Income Before Tax | -121.23% | -122.02% | 153.11% | -213.35% | -17.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -121.23% | -122.02% | 153.11% | -213.35% | -17.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.23% | -122.02% | 153.11% | -213.35% | -17.02% |
| EBIT | -5.50% | -12.19% | -86.90% | -186.68% | -113.29% |
| EBITDA | -6.51% | -13.34% | -98.60% | -201.96% | -119.02% |
| EPS Basic | 3.26% | 47.61% | -- | -581.15% | -143.08% |
| Normalized Basic EPS | -- | 53.81% | -- | -- | -- |
| EPS Diluted | 3.26% | 47.61% | -- | -581.15% | -143.08% |
| Normalized Diluted EPS | -- | 53.81% | -- | -- | -- |
| Average Basic Shares Outstanding | -- | 9,396.04% | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,187.86% | 9,396.04% | -- | 136.23% | -82.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |